Table 2 Study design and methodological outcomes (n = 248)
Variable | Number (%) |
|---|---|
Used qualitative dataa | 24 (9.7) |
Participants | 21 (8.5) |
Staff | 7 (2.8) |
Used progression criteria | 27 (10.9) |
Feasibility as primary objective | 77 (31.0) |
Feasibility as primary outcome | 46 (18.6) |
Feasibility outcomesa | |
Enrolment | 49 (19.8) |
Randomization | 14 (5.6) |
Participation | 4 (1.6) |
Retention | 23 (9.3) |
Compliance | 30 (12.1) |
Data completion | 25 (10.1) |
Feedback | 5 (2.0) |
Resources | 2 (0.8) |
Blinding | 3 (1.2) |
Timeliness of intervention | 9 (3.6) |
Acceptability | 7 (2.8) |
Adverse events | 14 (5.6) |
Protocol fidelity | 9 (3.6) |
None | 182 (73.4) |
Other | 15 (6.0) |
Sample size justificationa | |
Clinical outcome | 91 (36.7) |
Feasibility outcome | 24 (9.7) |
Literature (similar studies) | 46 (18.6) |
No justification | 114 (46.0) |
Other | 4 (1.6) |